Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Discussioni nella community
- (✅) Depot ist in der Vergangenheit sprunghaft gestiegen und wieder gefallen..
Hallo, heute ist mir aufgefallen, dass mein Portfolio am 16.12.2020 sprunghaft um circa 50.000€ gestiegen ist und am 24.05.2021 wieder um circa den gleichen Betrag gefallen. Vor und nach dem Zeitraum…
S Sebastian I in Schnack
4 6 - (✅) GSK Abspaltung Haleon GB00BMX86B70 nicht unterstützt
Servus, kann die Einbuchung nicht vornehmen, da GB00BMX86B70 nicht unterstützt wird.
Sven III in Schnack 6 16 - (✅) Neue GSK mit der WKN A3DMB5 nicht vorhanden
Nachdem ich die "alte" GSK ausgebucht habe wollte ich die neue GSK einbuchen; diese ist aber bei Euch leider noch nicht vorhanden - Könnt Ihr die WKN bitte noch einpflegen - Vielen Dank Gruß Ralf
RD Ralf Dietrich I in Schnack
1 1 - Bei "Holding Bearbeiten" Kein Handelsplatz gefunden
Ein Freund hat ebenfalls ein T1 Account und dieselbe Aktie wie ich:A87320L1031 A2P6PR Taat Lifestyle & Wellness. Komischer Weise wird bei ihm ein anderer Kurs angezeigt. Niemand hat den Handelsplatz…
Wichtel IV in Schnack 0 3
Notizie Vai al feed delle notizie
Billion-dollar deal with GSK pushes HUTCHMED stock higher
HUTCHMED signed an exclusive global development and licensing agreement with a GSK subsidiary for HMPL-A830, a KRAS‑EGFR‑directed antibody‑drug conjugate, with a potential total value of up to $1.295 billion. HUTCHMED will receive $110 million upfront and can earn up to $1.185 billion in milestones plus tiered royalties; GSK receives rights outside mainland China, Hong Kong, Macau and Taiwan, while HUTCHMED retains those territories. The deal is seen as validation of the ATTC platform and foresees the start of a global Phase I program in H2 2026. The news, together with a recent conditional approval of fanregratinib in China, drove an intraday share rise of about 14% to $13.95. » Altro su de.investing.com
GSK reports positive phase‑2 data for mRNA flu vaccine and plans phase‑3
GSK presented positive phase‑2 results for its mRNA influenza vaccine at a scientific conference; the vaccine elicited stronger immune responses in younger and older adults compared with licensed inactivated vaccines and was well tolerated. The company plans a phase‑3 efficacy study in September that will for the first time test an mRNA flu vaccine against HA and NA. If successful, GSK would move into direct competition with Moderna in the mRNA flu vaccine market. » Altro su deraktionaer.de
FDA places GSK drug Jemperli on priority review
The US drug regulator FDA is giving priority review to GSK’s colorectal cancer drug Jemperli (dostarlimab) and has set a review deadline through February. Jemperli also qualifies for the priority voucher program, which can shorten the approval process. GSK expects the drug could make chemotherapy, radiation and surgery unnecessary for some patients; the company also reported approval of Hibsago in Japan for chronic hepatitis B. GSK’s stock traded slightly weaker during the session. » Altro su finanzen.net
GSK appoints Philips CEO Roy Jakobs to the board of directors
GSK has appointed Roy Jakobs, currently CEO of Royal Philips, effective Sunday as an independent, non-executive member of the board. Jakobs, CEO of Philips since 2022 and with the company since 2010, will receive the usual annual fee of £122,258 and must hold shares worth twice that amount. The appointment was recommended by the nomination and corporate governance committee; after the decision the board has 13 members. » Altro su de.investing.com
Nuvalent reaches record high at $123.7 — GSK takeover offer at $124 per share
Nuvalent shares climbed to an all-time high of $123.7 and are only 1% below the 52-week high after investors showed confidence in the biotech. GSK has made a $10.6 billion takeover offer ($124 per share) for Nuvalent’s oncology assets, including candidates Zidesamtinib and Neladalkib. Valuation checks suggest the stock may be trading above its fair value, and analysts such as UBS and Bernstein have adjusted their ratings/price targets after the takeover news to neutral/market perform and $124, respectively. Despite high liquidity relative to debt, Nuvalent remains unprofitable as investors monitor further developments. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 10,19 Mld | 36,74% |
| Utile lordo | 7,59 Mld | 38,37% |
| Utile netto | 1,77 Mld | 0,80% |
| EBITDA | 3,79 Mld | 21,16% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 91,89 Mld € |
Numero di azioni | 4,01 Mld |
Massimo/minimo a 52 settimane | 28,60 € - 20,41 € |
Rendimento da dividendo | 3,46% |
Dividendi TTM | 0,79 € |
Beta | 0,30 |
Rapporto P/E | 17,70 |
Rapporto PEG | -0,86 |
Rapporto P/B | 4,09 |
Rapporto P/S | 2,28 |
Profilo aziendale
GSK plc, insieme alle sue controllate, si occupa della creazione, scoperta, sviluppo, produzione e commercializzazione di prodotti farmaceutici, vaccini, farmaci da banco e prodotti per la salute destinati ai consumatori nel Regno Unito, negli Stati Uniti e a livello internazionale. L'azienda opera attraverso quattro segmenti: Pharmaceuticals, Pharmaceuticals R&D, Vaccines e Consumer Healthcare. L'azienda offre prodotti farmaceutici comprendenti medicinali nelle aree terapeutiche come quella respiratoria, HIV, immuno-infiammazione, oncologia, antivirali, sistema nervoso centrale, cardiovascolare e urogenitale, metabolismo, antibatterici e dermatologia. Fornisce inoltre prodotti per la salute destinati ai consumatori nelle categorie benessere, salute orale, nutrizione e salute della pelle. L'azienda offre i suoi prodotti per la salute destinati ai consumatori sotto forma di spray nasali, compresse, sciroppi, pastiglie, gomme e cerotti transdermici, caplets, sciroppo in gocce per neonati, sospensione liquida, salviette, gel, compresse effervescenti, dentifrici, spazzolini da denti, collutori, adesivi e detergenti per protesi dentarie, creme topiche e cerotti non medicati, burro cacao, caramelle gommose e soft chews. Ha accordi di collaborazione con 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; e CureVac AG., nonché una partnership strategica con IDEAYA Biosciences, Inc. e Vir Biotechnology, Inc. L'azienda era precedentemente nota come GlaxoSmithKline plc e ha cambiato denominazione in GSK plc nel maggio 2022. GSK plc è stata fondata nel 1715 ed ha sede a Brentford, nel Regno Unito.
| Nome | GlaxoSmithKline |
| CEO | Luke Victor Miels |
| Sede centrale | London,
gl Regno Unito |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 01/07/1988 |
| Dipendenti | 66.841 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Pnk | GLAXF |
London Stock Exchange | GSK.L |
XETRA | GS71.DE |
Frankfurt | GS71.F |
Düsseldorf | GS71.DU |
Hamburg | GS71.HM |
London | GSK.L |
SIX | GSK.SW |
München | GS71.MU |